Coherus Oncology (CHRS) Other Non Operating Income (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Other Non Operating Income data on file, last reported at $1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non Operating Income rose 649.73% year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (up 109.48% YoY), and the FY2025 full-year result was $1.6 million, up 112.45% from the prior year.
• Other Non Operating Income improved to $1.4 million in Q1 2026, from -$3.7 million in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $2.9 million in Q2 2025 to a low of -$19.0 million in Q4 2024.
• A 5-year average of -$1.0 million and a median of $1.4 million in 2022 frame the typical range for Other Non Operating Income.
• Across the five-year window, Other Non Operating Income jumped 5300.0% in 2023 and slumped 14667.44% in 2024, its largest moves.
• Tracing CHRS's Other Non Operating Income over 5 years: stood at $1.3 million in 2022, then tumbled by 109.63% to -$129000.0 in 2023, then tumbled by 14667.44% to -$19.0 million in 2024, then jumped by 80.81% to -$3.7 million in 2025, then surged by 138.35% to $1.4 million in 2026.
• Business Quant data shows CHRS's Other Non Operating Income at $1.4 million in Q1 2026, -$3.7 million in Q4 2025, and $2.1 million in Q3 2025.